



Center for Harm Reduction Services (CHRS)

Janelle Hodgson, MPH, Epidemiologist

Jasmine Lopes, MPH, Epidemiologist


May 22, 2024

SSP Data Updates


**SFY24-Q3 Program Data (January 1, 2024 -
March 31, 2024)**

New Participants Registered & Total Participants Served


Number of New Participants Registered Q3-FY23 and Q3-FY24



Number of Participants Served Q3-FY23 and Q3-FY24




Syringes Distributed/Collected



Direct Services

A total of **46,164 direct services** were provided in FY24-Q3




Wound Care

A total of **13,318 wound care direct services** were provided in FY24-Q3

- Hands on wound care: 465
- Wound care kit supplies: 12,853


Referrals/Linkage to Care

A total of **14,992 referrals/linkages to care** were provided in FY24-Q3



Rapid Analysis of Drugs (RAD) Update

Participating Syringe Service Programs



Samples Collected


- Sample Collection began in October 2021 and is continuing
- As of 04/30/2024 2,736 samples have been tested.
- 17 of the 27 SSPs in Maryland collect samples.
 - Covering 12 jurisdictions

RAD Data Disclaimers

- Convenience Sampling -
 - RAD is a completely voluntary program that Maryland SSP participants can choose to engage in
 - Not all MD jurisdictions have an SSP that participate in RAD
- No personally identifiable data is collected, therefore we do not know how many participants are accounted for in the sample size


RAD gives us some indication of the near real time drug market in Maryland, but it should not be considered as fully representative.

RAD Sampling by Jurisdiction



Source: Rapid Analysis of Drugs (RAD), Reporting Period 10/1/2021 to 4/30/2024


RAD Sampling by Jurisdiction, OCT 2021- April 2024



Source: Rapid Analysis of Drugs (RAD), Reporting Period 10/1/2021 to 4/30/2024

Note: Data is preliminary and subject to change.


RAD Compounds, OCT 2021- April 2024



Source: Rapid Analysis of Drugs (RAD), Reporting Period 10/1/2021 to 4/30/2024

Samples Containing Cocaine


- 38.6% of samples tested contained cocaine.
- In CY24 Q1 (January - March) there were a total of 77 samples that contained cocaine.
- 19.5% decrease from the previous quarter (CY23 Q4)
- 14% decrease in samples containing cocaine from same time last year (CY23 Q1)



Note: Data is preliminary and subject to change.

Samples Containing Xylazine

- 33.2% of samples tested contained xylazine.
- In CY24 Q1 (January - March) there were a total of 111 samples that contained xylazine.
- 24.5% increase from the previous quarter (CY23 Q4)
- 16.1% increase in samples containing xylazine from same time last year (CY23 Q1)




Note: Data is preliminary and subject to change.

DEPARTMENT OF HEALTH

Source: Rapid Analysis of Drugs (RAD), Reporting Period 10/1/2021 to 4/30/2024

Samples Containing Fentanyl & Fentanyl Analogs

- 46.1% of samples tested contained fentanyl.
- In CY24 Q1 (January - March) there were a total of 128 samples that contained fentanyl.
- 26.1% increase from the previous quarter (CY23 Q4)
- 6.7% increase in samples containing fentanyl from same time last year (CY23 Q1)




Note: Data is preliminary and subject to change.

DEPARTMENT OF HEALTH

Source: Rapid Analysis of Drugs (RAD), Reporting Period 10/1/2021 to 4/30/2024

Samples Containing Other Opioids

- 0.7% of samples tested contained other opioids.
- In CY24 Q1 (January - March) there were no samples that contained other opioids.




Note: Data is preliminary and subject to change.

DEPARTMENT OF HEALTH

Source: Rapid Analysis of Drugs (RAD), Reporting Period 10/1/2021 to 4/30/2024

Samples Containing Amphetamines

- 6.9% of samples tested contained amphetamines.
- In CY24 Q1 (January - March) there were a total of 32 samples that contained Amphetamines.
- 1.5% decrease from the previous quarter (CY23 Q4)
- 6.8% increase in samples containing amphetamines from same time last year (CY23 Q1)




Note: Data is preliminary and subject to change.

DEPARTMENT OF HEALTH

Samples Containing Heroin & Related Compounds

- 1% of samples tested contained heroin.
- In CY24 Q1 (January - March) there were a total of 1 sample that contained heroin.
- 0.5% decrease from the previous quarter (CY23 Q4)
- 1.3% decrease in samples containing heroin from same time last year (CY23 Q1)



Note: Data is preliminary and subject to change.

DEPARTMENT OF HEALTH

Source: Rapid Analysis of Drugs (RAD), Reporting Period 10/1/2021 to 4/30/2024

THANK YOU!

Questions regarding Syringe Service Programs please email:

mdh.syringeservices@maryland.gov

Contact Us:

Janelle Hodgson

janelle.hodgson@maryland.gov

Jasmine Lopes

Jasmine.lopes@maryland.gov

Maggie Rybak

Margaret.rybak@maryland.gov